LUCIRA™ HEALTH Hires Ghazi Kashmolah as Chief Quality Officer and EVP Regulatory Affairs
August 23 2021 - 6:00AM
Business Wire
Life science professional expands Lucira’s
management team
Lucira Health, Inc. (“Lucira Health” or
“Lucira”) (NASDAQ: LHDX), a medical technology company focused on
the development and commercialization of transformative and
innovative infectious disease test kits, today announced life
science professional Ghazi Kashmolah has joined the company as
Chief Quality Officer and Executive Vice President Regulatory
Affairs.
“Ghazi is a strong addition to Lucira’s executive leadership
team, and we are delighted to have him aboard,” said CEO Erik
Engelson.
Ghazi comes to Lucira with more than 30 years experience in
quality and regulatory work leading, developing and transforming
global quality in the medical device and biotech industries. Most
recently, he was Chief Quality Assurance, Regulatory Affairs, and
EH&S Officer at Orchid Orthopedic Solutions. Prior to that, he
led quality and regulatory affairs as SVP of QA/RA for DJO Global,
VP of QA/RA at OSI Systems, and VP of Global QA/RA at Life
Technologies. At Cardinal Health, Ghazi was VP, Global Operations
including manufacturing, supply chain, and quality. Ghazi holds BS
and MS degrees in electrical engineering, as well as an Executive
MBA. He will play a valuable role in expanding the utility and
availability of Lucira’s consumer-friendly test.
“I am excited to be joining this dynamic company, particularly
during the COVID pandemic. Lucira’s accurate and easy-to-use
molecular test has already helped hundreds of thousands of people,”
said Kashmolah. “Because this platform technology has the potential
to be used to diagnose a variety of infectious diseases, I’m
confident its global impact will grow rapidly as we expand its
capabilities.”
About Lucira Health
Lucira is a medical technology company focused on the
development and commercialization of transformative and innovative
infectious disease test kits. Lucira’s testing platform produces
lab quality molecular testing in a single-use, consumer-friendly,
palm-size test kit powered by two AA batteries. Lucira designed its
test kits to provide accurate, reliable, and on-the-spot molecular
test results anywhere and at any time. The LUCIRA™ CHECK IT
COVID-19 Test Kit (OTC) and LUCIRA™ COVID-19 All-In-One Test Kit
(Rx) are designed to provide a clinically relevant COVID-19 result
within 30 minutes from sample collection. For more information,
visit www.lucirahealth.com.
Forward Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are “forward-looking statements”
within the meaning of the Private Securities Litigation Reform Act
of 1995. Such forward-looking statements include statements
regarding, among other things, Lucira’s continued development and
commercialization of its transformative and innovative infectious
disease test kits and ability to increase sales. Because such
statements are subject to risks and uncertainties, actual results
may differ materially from those expressed or implied by such
forward-looking statements. Words such as “can” “plans,” “will,”
“may,” “anticipates,” “expects,” “potential” and similar
expressions are intended to identify forward-looking statements.
These forward-looking statements are based upon Lucira’s current
expectations and involve assumptions that may never materialize or
may prove to be incorrect. Actual results could differ materially
from those anticipated in such forward-looking statements as a
result of various risks and uncertainties, including the impact to
our business of the ongoing COVID-19 pandemic; any impact on our
ability to market our products; demand for our products due to
deferral of procedures using our products or disruption in our
supply chain; our ability to achieve or sustain profitability; our
ability to gain market acceptance for our products and to
accurately forecast and meet customer demand; our ability to
compete successfully; our ability to enhance our product offerings;
development and manufacturing problems; capacity constraints or
delays in production of our products; maintenance of coverage and
adequate reimbursement for procedures using our products; and
product defects or failures. These and other risks and
uncertainties are described more fully in the “Risk Factors”
section and elsewhere in our filings with the Securities and
Exchange Commission and available at www.sec.gov, including in our
most recent Annual Report on Form 10-K and Quarterly Report on Form
10-Q. Any forward-looking statements that we make in this
announcement speak only as of the date of this press release, and
Lucira assumes no obligation to update forward-looking statements
whether as a result of new information, future events or otherwise
after the date of this press release, except as required under
applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210823005197/en/
Media Contact Kevin Knight media@lucirahealth.com
206-451-4823
Investor Contact Greg Chodaczek
Investorrelations@lucirahealth.com 347-620-7010
Lucira Health (NASDAQ:LHDX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Lucira Health (NASDAQ:LHDX)
Historical Stock Chart
From Sep 2023 to Sep 2024